New collaborations give life science companies access to the latest cutting-edge technology

The purpose of the investment is to speed up the innovation work in Swedish life science companies so that new solutions are more quickly put to clinical trials, into care and reach more patients. It is about more accurate methods for making a diagnosis and advanced individually tailored treatments such as cell therapy, so-called precision medicine. The development of precision medicine is accelerating, thanks in large part to new technology.

- I Sverige has made large investments in infrastructure facilities. With this investment, more people get the opportunity to use the advanced methods and cutting-edge technology and make important progress in the development of precision medicine, says call manager Anna Tegnesjö.

The 13 companies receive a total of SEK 13 million over the course of a year to collaborate with a so-called research infrastructure.

Through the collaboration with the infrastructure, the company gains access to qualified expertise, advanced methods and cutting-edge technology that can contribute to faster steps forward in the company's innovation work. The collaboration can speed up the development of the innovation and provide the opportunity to test the product during development.

For several of the projects in the venture, the collaboration will contribute to sharpening, quality assurance and scaling up production so that it, for example, meets the so-called GMP standard (Good Manufacturing Standard). With production on a larger scale, new advanced therapies become more quickly available to more patients.

See project that receives funding

Footnote: Link image comes from Testa Center